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Abstract
The problem of malnutrition concerns most patients in the advanced stages of cancer. Nutrition and food
are synonymous with the continuation of life for patients and their families and friends. In this paper, the
methods of oral, enteral and parenteral nutrition are discussed, together with their advantages and the
controversies connected with them and their effects on survival time and the quality of life.
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Introduction
Those patients who, yesterday, were still dying
of cancer, today, owing to progress in medicine,
survive until malnutrition becomes the main factor
causing death [1].
Malnutrition is a problem for most patients with
advanced cancer. Malnutrition causes impairment
to the quality of life, immunity and body functions.
It is responsible for the increased incidence of dis-
eases, mostly of various infections, and, in conse-
quence, brings the patient's death forward. It is be-
lieved that in 5–20% of cancer patients, cachexia is
the direct cause of death [2, 3]. Every year, two
million people worldwide die from cachexia [4, 5]:
these are mainly patients with gastrointestinal and
lung cancers.
Malnutrition associated with cancer disease is de-
termined by many factors: in the first place by reduc-
tion of the amount of food consumed (its main caus-
es include obstruction rendering gastrointestinal pas-
sage difficult, vomiting, pain and depression), reduc-
tion of intestinal absorption, and metabolic changes
(glucose intolerance, insulin resistance, increased glu-
coneogenesis from amino acids and lactates, de-
creased lipogenesis, and disrupted protein metabo-
lism) [6]. Protein loss is the main factor responsible
for mortality in malnutrition. In healthy adults 33–
37% loss of ideal body mass, which corresponds to
60–75 days of starvation, is regarded as critical [7].
On the other hand, in the advanced stage of
cancer, 63% of patients feel no hunger and 34%
feel only slight hunger; 62% of patients feel no thirst
or only slight thirst [8]. Thirst, however, is not con-
nected with the degree of dehydration [14]. Oral
hygiene measures, such as mouth rinsing, ice cube
sucking and consumption of liquid food through a
straw, bring relief.
“Deux extremes: exclure la raison, admettre uniquement la raison”
“Two extremes: to exclude reason, to act according only to reason”
“Thoughts,” Blaise Pascal
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The problem of nutrition concerns mainly cancer
patients who can be classified in the following
groups:
— potentially curable patients who require aggres-
sive chemo- and radiotherapy and surgical treat-
ment;
— patients regarded as cured, presenting with in-
testinal failure due to resection or radiation-in-
duced enteritis;
— patients with advanced cancer, refractory to treat-
ment, presenting with alimentary failure.
Although nutrition of the first two groups of
patients is widely accepted, patients from the third
group still constitute a current problem open to
discussion. These patients will die of disease pro-
gression irrespective of whether they are fed or not.
Sometimes their being fed is still necessary, should
we assume based on medical knowledge that they
would die from starvation earlier than from the di-
rect cause of the disease.
Oral nutrition
The American Dietetic Association (ADA) suggests
the following mode of therapeutic management when
starting nutrition for a palliative care patient [9]:
1. Consumption per os of food, in accordance with
the patient's desires.
2. The introduction of artificial and natural nutri-
tional supplements.
3. Family participation in nutrition.
4. The elimination of dietary restrictions, e.g. so
called “unhealthy” food.
5. Respecting the patient’s freedom of choice: many
patients consume meals to please their families.
6. The treatment of symptoms and signs that make
food consumption difficult.
The following can also be added to the list:
— adaptation of the consistency, volume and fre-
quency of meals to the alimentary capabilities of
the patient;
— prevention of mouth dryness: application of wa-
ter 2–3 ml with a pipette, mouth rinsing, ice
sucking, pineapple chewing, artificial saliva;
— treatment of anorexia: megestrol acetate, dex-
amethasone;
— treatment of nausea and vomiting: methoclo-
pramide;
— treatment of complaints of pain in the oral cavi-
ty, or swallowing disorders;
— prevention of constipation;
— treatment of diarrhoea;
— diagnosis and treatment of depression.
Nutrition and survival time
The expected survival time is possibly the most
important criterion when making the decision about
the introduction of feeding, particularly artificial
nutrition. Its determination is extremely difficult and
it is usually optimistically overestimated [10]. The
Karnofsky scale (index), which determines in per-
centage values the physical fitness of patients treat-
ed for cancer disease, seems to be a rather good
parameter: a 50% result indicates the risk of death
in six months (most frequently two months).
Other described criteria include:
— body weight loss of over 10 kg and a Mini Men-
tal test result of below 24 and coexistent dysph-
agia — the estimated survival time is under four
weeks [11];
— a palliative prognostic index combining the re-
sult on the ECOG scale describing a patient's vi-
tal activity, oral administration of food, absence
of oedema, resting dyspnoea, and hallucinations.
The index determines the expected survival time
over six weeks with 77% specificity and 80% sen-
sitivity [12];
— a palliative prognostic score uses the following
symptoms and signs for the assessment of a pa-
tient's condition (prediction of survival time over
30 days with 87% probability): the Karnofsky
index, anorexia, dyspnoea, leucocyte count and
lymphocyte percentage [13].
Knowing that someone can survive for approxi-
mately two months without food, it seems reason-
able to introduce artificial nutrition for patients re-
quiring it, if the estimated survival time is over two
or three months.
According to the ADA, the remaining criteria for
the introduction of artificial feeding include the fol-
lowing:
— evaluation of benefits and risk;
— the choice of the patient, having previously been
informed about the food administration route;
— the availability of staff providing enteral and
parenteral feeding.
Enteral nutrition
The main indication for starting enteral nutrition
are malignancies of the upper segment of the ali-
mentary tract that render swallowing impossible,
with normal function maintained in the gastrointes-
tinal tract. Gastric tubes are replaced by a percuta-
neous endoscopic gastrostomy (PEG). Numerous clin-
ical studies confirm a higher early mortality rate in
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patients following PEG application [15, 16], which is
connected with decreased albumin levels in such
patients or those with dementia [17, 18]. In other
studies, no high percentage of serious complica-
tions following PEG application were found, although
the following complications were reported in 5-13%
of cases: wound infection, gastric content leakage,
intestinal obstruction [19–22].
Statistical data (1992) demonstrate that 415 pa-
tients per 1 million population in the USA and 40
per 1 million in Great Britain have been fed by the
enteral route. On the either side of the Atlantic,
patients with cancer account for 40% of those fed
by the enteral route: most of them live only a month
but 30% manage to survive a year.
Another group of palliative care patients are those
with amyotrophic lateral sclerosis, in whom swal-
lowing disorders develop rather early in the course
of the disease. In such patients, the introduction of
enteral nutrition can prolong life, reducing the risk
of aspiration and choking. Of course, those patients
are fully aware and take the decision about begin-
ning the nutrition independently [23].
Compared with parenteral nutrition, enteral feed-
ing is cheaper, has fewer adverse effects, allows for
the maintenance of the intestinal barrier [24], and,
although it causes no increase in lean body mass in
cancer patients [25], it partially prevents its decrease,
reduces the concern of the caregivers and improves
the psychological condition of the patients them-
selves [26, 27].
Parenteral nutrition
In a review of international literature on the nu-
trition of patients in the terminal stages of diseases,
the most controversial factor is the application of
total parenteral nutrition (TPN) in palliative care pa-
tients [28]. Until now, no beneficial effect of TPN
has been proven on parameters other than the strictly
nutritional, and the adverse effects, which do not
occur rarely, are also stressed.
Parenteral nutrition was applied for the first time
in animals in 1656 by Wren. He administered wine,
opium, and oleic acid intravenously. In 1840 Ber-
nard subcutaneously injected animals with a solu-
tion of egg albumin, milk, and cane sugar. Biedl and
Krause in 1896 administered glucose solution to
humans intravenously but only in 1967 did Dudrick,
applying completely parenteral nutrition, manage
to obtain normal growth and development, first in
puppies and, a year later, in a child. This started the
development of parenteral nutrition as a therapeu-
tic method and a great boom in the pharmaceutical
industry, with the creation of a branch worth many
billions of dollars [23,29].
Considering the pros and cons in the context of
TPN in palliative care patients, it seems reasonable
to answer the following questions:
— does parenteral nutrition prolong the survival
time?
— does parenteral nutrition improve the quality of
life?
— does parenteral nutrition prolong the process of
dying?
Federico Bozetti from the Italian Enteral and
Parenteral Nutrition Society believes that in the 21st
century parenteral nutrition should not be regarded
as an extraordinary therapeutic method: we all used
that atypical administration route for nutrients dur-
ing intrauterine life. TPN can be applied at home,
with the family's help. Parenteral nutrition should
not be made unavailable to patients with cancer
disease refractory to treatment simply because its
effectiveness has not been confirmed by evidence-
based medical criteria [30]. Bozetti compares this
situation with the administration of expensive ther-
apy with gemcytabine in patients with advanced
pancreatic cancer, in whom the survival time is 3–5
months and the therapy is applied routinely.
In another publication [31] the same author sug-
gests using TPN in patients who could die earlier
from malnutrition than from progression of the dis-
ease. Should any doubts arise as to the validity of
the practice of parenteral nutrition, Bozetti suggests
adopting the “try it and see” strategy. The effects of
TPN are easily and rapidly reversible: in the case of
the absence of benefits, nutrition can be stopped
and the “wrong” decision is a lesser error than the
lack of the introduction of a possibly beneficial treat-
ment [32].
Duerksen et al carried out studies on a group of
patients with alimentary tract malignancies refrac-
tory to surgical treatment and with alimentary tract
obstruction, in whom the estimated survival time
after aggressive chemotherapy was several months.
On the basis of the results obtained, they concluded
that TPN was beneficial in the case of an estimated
survival time of over 60 days, the minor complica-
tions of TPN that occurred having no influence on
mortality, and biological parameters were not help-
ful in identifying those patients in whom TPN could
have been more beneficial [33].
Even Loprinzi from the Mayo Clinic, although
sceptical in his opinion in Current Controversies in
Cancer, admits that in spite of the absence of well-
Advances in Palliative Medicine 2008, vol. 7, no. 1
www.advpm.eu36
documented data on the validity of the application
of parenteral nutrition in patients with advanced
cancer, there are some situations when such inter-
vention is justified. They include post-resection in-
testinal failure, radiation- or chemotherapy-induced
enteritis and cancer dissemination in the abdominal
cavity (carcinomatosis) without failure of the remain-
ing organs.
About 40% of patients fed parenterally are those
with cancer disease at every stage of progression.
That percentage varies in different countries: 80%
in Sweden, 60% in the Netherlands, 40% in the
USA, 27% in France, and only 5% in Great Britain.
Those patients are fed for four months on average
and about 30% of them survive for over a year [34].
Parenteral nutrition and the quality
of life
Few publications are available describing the
quality of life of patients with advanced cancer in
whom TPN was applied. In a study in 2002 [36],
Bozetti, quoted above, evaluated the quality of life
for patients with advanced cancer subjected to
parenteral nutrition in several Italian centres. For
the assessment of quality of life, the Rotterdam scale
was used with a form completed by the patients
beginning TPN and again at monthly intervals. The
mean TPN duration was four months. The condition
of the patients assessed by the Karnofsky scale was
stable until the third month before death. A month
following the beginning of TPN, no impairment of
the quality of life was observed. The quality of life
level was stable until approximately the second
month before death. In their final conclusion the
authors reported that TPN can prolong survival time
by up to seven months in one third of the patients,
improve the quality of life in 20-40% or at least
maintain it at an unchanged level until the second
month before death. The patients who qualify for
TPN should have a Karnofsky scale score of 50% and
should give consent to the application of such treat-
ment, the duration of which is estimated to be at
least one month.
In Stockholm, a descriptive study of the quality
of life was conducted in palliative care patients in-
cluded on a programme of home parenteral nutri-
tion, as well as in their families or caregivers [35].
The most frequently stressed positive aspects of that
activity included a feeling of safety connected with
frequent visits of “the feeding team”, a reduction in
internal tension connected with the “obligation” to
have meals, and even body weight gain and increase
of appetite. Only isolated adverse effects were ob-
served, such as nausea, vomiting, headaches (con-
nected with the rate of formula application rather
than with the feeding itself), and limitations in so-
cial contact. In most patients parenteral nutrition
administered at night 3–4 times weekly with week-
end-long intervals was complementary to oral feed-
ing. No negative opinions of the patients were re-
corded, possibly because some of them discontin-
ued the home nutrition programme and were ex-
cluded from the study. In addition to that, Sweden
is a country with a highly-developed social welfare
system (a model of the welfare state), where the
artificial nutrition of terminally ill patients is applied
almost routinely.
In the study by Howard et al the financial cost,
survival time and quality of life of patients subject-
ed to a home TPN programme were evaluated [37].
It was found that the therapy was safe, particularly
in its short-term application, as in the case of can-
cer patients: 2–6 months (a short survival time),
and 2–3 years in female patients with metastatic
ovarian cancer (there is a better prognosis in the
case of malignancies associated with sex). Accord-
ing to the authors, TPN complications were respon-
sible for only 1% of deaths; the remaining causes
mainly included underlying disease progression and
diseases of other organs. It was confirmed that
40% of parenterally fed patients were those with
cancer disease, and 20% of the patients survived
one year. The cost of the home nutrition programme
was only half of that during hospitalization and
was lower in younger patients. Quality of life was
assessed in emotional and social terms and in re-
spect of physical parameters. The observed quality
of life level was low in the first year of feeding and
increased gradually with TPN continuation, reach-
ing a result comparable with that in a healthy pop-
ulation after about four years. Unfortunately, no
separate analysis was carried out in cancer patients
with a short survival time.
In Great Britain — the country where only a low
percentage of parenterally fed patients are those
with cancer disease — a study was conducted to
assess how nutritional habits could be influenced
and how patients with advanced disease could be
helped [38]. Most patients with cancer present with
an appetite decrease, an early feeling of satiety, an
aversion to eating and a refusal to take food, which
led in 30–80% of patients to anorexia precipitating
death. Most patients and their caregivers accept
these changes, regarding them as a transitional stage
between life and death. Others try to deal with the
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problem, only to be met with incomprehension from
the caregivers, who believe that a good caregiver
can persuade the patient to eat.
Nutrition in paediatrics
Considering the problem of nutrition for patients
in the terminal stage of disease, the differences in
the management of very young patients should be
stressed [39]. This concerns four groups of children:
— children with potentially curable diseases (neo-
plasms, circulatory failure);
— children with diseases in which intensive treat-
ment can prolong survival time (intestinal fail-
ure, cystic fibrosis);
— children with diseases in which only palliative
treatment is applied (neurodegenerative diseas-
es);
— children with diseases leading to invalidism, of-
ten neurological (e.g. metabolic, mitochondrial
diseases).
Nutrition for children is one element of the glo-
bal care of very young patients, although it cannot
be forgotten that its purpose is not the prolonga-
tion of survival time at any cost.
In the first group, therefore, the main aim is
improvement of a child's functioning and comfort
and a reduction of the symptoms and signs of weak-
ness. Enteral nutrition with a tube failed to give the
expected results, in some cases a gastrostomy was
better tolerated but TPN was the most frequently
chosen method of nutrition.
Nutrition in the second group of children not
only contributed to survival prolongation but also
to an improvement in life quality. After 10–25 years
of TPN, most of those patients reached a certain
social and professional status.
In groups 3 and 4, the introduction of artificial
nutrition is very often necessary and usually the ap-
propriacy of such treatment is unquestionable. For
most members of teams treating children in the
terminal stage of disease, their nutrition is an inte-
gral part of the care provided for them. Is there,
therefore, a time limit determining when the artifi-
cial nutrition of patients should be discontinued?
The nutrition becomes permanent and then, for eth-
ical and moral reasons, it should not be stopped. In
spite of adverse effects, gastric tubes (with the risk
of infection in the upper airways, accidental or in-
tentional removals, inflammatory conditions of the
oesophagus and stomach), a gastrostomy (insertion
under general anaesthesia, tube obstruction, abdom-
inal pain and vomiting caused by too rapid an ad-
ministration of formula), and TPN (with a risk of
disturbing the blood-intestine barrier and bacterial
translocation) are used.
Hydration in palliative medicine
The last issue to discuss is the problem of the
hydration of terminally ill patients. Cessation of the
consumption of fluids and food, increased sweat-
ing, vomiting, and sometimes diarrhoea are the main
causes of dehydration in the process of dying. The
families of patients very often take note of the fact
that their kin will not die of hunger because they
simply will not have time: cancer will kill them soon-
er. However, they can die of thirst and dehydration.
Are there any clear indications for hydrating all ter-
minally ill patients?
Here also, the opinions of scientists are diver-
gent: some believe that dehydration can be respon-
sible for apathy, depression, dysphagia, or orthos-
tatic arterial pressure drops [40, 41]; others, howev-
er, point to benefits connected with dehydration:
the reduction of bronchial secretion leading to im-
provement of respiratory comfort, a decrease in cen-
tral and peripheral oedema, the reduction of vomit-
ing and urination frequency, and a decrease in pain
and discomfort due to acidosis [42].
Presently, most physicians believe that dehy-
dration is better tolerated by patients than the risk
connected with intense hydration, especially if the
dehydration developed gradually and was not
caused by sudden reversible episodes (diarrhoea or
vomiting). Of course, in some cases, e.g. in hyper-
calcaemia, hydration is desirable and even neces-
sary.
Although 63% of terminally ill patients feel no
hunger [43], the feeling of thirst in the case of dehy-
dration is reported significantly more frequently —
by over 80% of patients [44,45], or according to
other authors by 62% [8] — but it is not proportion-
al to the degree of dehydration [14].
The demand for water in cancer patients is far
lower than that in healthy people. Firstly, cachexia
leads to an increase of the extracellular space; sec-
ondly, there is possibly an overproduction of antidi-
uretic hormone; thirdly, cancer is frequently dissem-
inated in the peritoneal cavity and excessive fluid
supply can exacerbate its symptoms and signs. In
1946, Gamble had already proved that the supply of
glucose solution (frequently used during hydration)
decreases renal sodium excretion, thus increasing
the extracellular space, which is already greater in
cancer disease.
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To hydrate or not to hydrate?
In 2006 the results were published of a multicen-
tre study assessing biological parameters and water
balance in patients with disseminated malignant
process in the abdominal cavity who had been sub-
jected, or not, to artificial hydration [46]. A signifi-
cantly lower albumin level and, therefore, lower on-
cotic pressure were observed in the hydrated pa-
tients, while no differences were found in the levels
of non-protein nitrogen/creatinine, sodium or po-
tassium. The mean water balance was 400 ml daily
and only 20% of the patients had a positive balance.
It should be stressed that the non-protein nitrogen/
creatinine level increased in the last three weeks of
life, irrespective of whether the patients were hy-
drated or not.
The hypothesis was put forward that in termi-
nally ill patients intravascular dehydration is caused
by fluid escape into the intercellular space and not
by complete loss of water. Active hydration of such
patients, therefore, fails to increase the volume of
intravascular space: water “escapes” from the ves-
sels as a result of greater permeability of the endot-
helium and reduced oncotic pressure. The assess-
ment of water balance in those patients was not
correlated with clinical signs of dehydration/fluid
retention.
In the light of these results, the active hydration
of terminally ill patients seems pointless.
Mouth dryness is a frequent manifestation ac-
companying dehydration. The management in this
case includes the treatment of mycosis, oral hygiene
measures and dietary recommendations (if the pa-
tient takes food per os). Close attention should be
paid to oral hygiene maintenance: rinsing with anti-
septic solutions, moistening of the lips and tongue,
the administration of low volumes of fluids, the suck-
ing of ice cubes and lumps of pineapple, chewing
gum, etc.
In the case of a necessity for hydration (e.g. as a
result of dramatic dehydration due to diarrhoea or
vomiting) the least invasive method should be cho-
sen. If no central access point (vascular port) is avail-
able, the subcutaneous administration of 0.9% NaCl
solution, 500 ml daily e.g. during the night seems
appropriate.
Conclusions
In 2001, French specialists in malignant diseases,
on the basis of the available world literature, pre-
pared “The standards, options and recommenda-
tions for nutrition of adult patients with advanced
and terminal cancer disease”. These are as follows:
1. Nutrition and hydration of patients in the termi-
nal stages of cancer disease should be instituted
or continued if its purpose includes improvement
of the quality of the patient's life or the allevia-
tion of some clinical symptoms and signs. The
priority is to maintain the oral route of food/fluid
administration as long as possible.
2. Enteral nutrition is recommended in patients with
malignancies of the upper airways and alimenta-
ry tract, which completely or partially render food
taking impossible, which could lead to cachexia
and death in a short time period.
3. Parenteral nutrition can prolong survival time in
patients with malignancies of the alimentary tract
or cancer dissemination in the abdominal cavity
leading to intestinal obstruction in whom the
estimated survival time is greater than three
months [47].
The position of the Polish Society of Enteral and
Parenteral Nutrition is similar: the oral route is the
priority, with maintained alimentary tract function
the enteral route should be used; while the intro-
duction of parenteral nutrition is valid when the
estimated survival time is longer than two months.
On the other hand, Polish specialists in palliative
medicine approach the issue of nutrition slightly
more rigorously. This is possibly connected with the
British model of palliative care accepted in Poland
(only 8% of patients receiving enteral and parenter-
al nutrition in Great Britain are those with cancer
disease), or with underinvestment in the health ser-
vice, or, possibly, with the logistical management of
patients with an estimated survival time shorter than
three months.
The question of whether to feed or not to feed
remains, therefore, a topical issue.
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